VTVT

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

• vTv Therapeutics (VTVT) Received FDA Orphan Drug Designation for HPPD, an Investigational Therapy for Sickle Cell Disease.Oct 9, 2026
• vTv Therapeutics Reinitiates Screening in CATT1 Phase 3 Trial to Evaluate Liver-Selective Glucokinase Activator "Cadisegliatin" for Type 1 DiabetesMay 16, 2025

News

• vTv Therapeutics announces an oral presentation at the 2026 Breakthrough T1D Clinical and Research CongressOct 10, 2026
• vTv Therapeutics receives FDA Orphan Drug Designation for HPPD in sickle cell diseaseOct 9, 2026
• vTv Therapeutics receives FDA Orphan Drug Designation for HPPD in sickle cell diseaseOct 8, 2026
• vTv Therapeutics completes enrollment in the Phase 3 CATT1 trial of cadisegliatin in type 1 diabetesOct 5, 2026
• vTv Therapeutics amended license agreement with Newsoara for PDE4 inhibitor HPP737Feb 2, 2026